Animal models of chronic thromboembolic pulmonary hypertension

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, yet life-threatening disorder characterized by persistent pulmonary vascular obstruction and elevated pulmonary artery pressure, with progressive remodeling and subsequent right heart failure. Despite substantial progress in elucidating the pathophysiology of CTEPH, the molecular mechanisms driving disease initiation and progression remain incompletely defined. Bridging these knowledge gaps and enabling the development of CTEPH-specific therapeutic strategies depend on experimental models that faithfully recapitulate the key pathological features observed in patients. A wide range of small- and large-animal models has therefore been established to mimic CTEPH development, each offering specific strengths and inherent limitations. Small animal models are relatively inexpensive, readily amenable to genetic manipulation, and well suited for high-throughput mechanistic investigations. However, their capacity to reproduce the complex pulmonary vascular architecture and hemodynamic characteristics of human disease is limited. By comparison, large-animal models more closely approximate human pulmonary anatomy and cardiovascular physiology, making them particularly valuable for detailed hemodynamic measurements and advanced imaging studies. Their broader application, however, is constrained by high financial costs, ethical considerations, and the need for specialized surgical and monitoring techniques. In this review, we provide an overview of currently available animal models of CTEPH, with emphasis on their methodological features, their ability to reproduce clinically relevant disease characteristics, and their potential utility in preclinical and translational research.

Keywords

animal models / chronic thromboembolism pulmonary hypertension / pulmonary hypertension / pulmonary vascular remodeling

References

[1] Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med. 2014; 2: 573-582.

[2] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43: 3618-3731.

[3] Jansa P, Ambrož D, Kuhn M, et al. Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic. Pulm Circ. 2022; 12:e12038.

[4] Kerr KM, Elliott CG, Benza RL, et al. The United States chronic thromboembolic pulmonary hypertension registry: protocol for a prospective, longitudinal study. JMIR Res Protoc. 2021; 10:e25397.

[5] Simonneau G, Hoeper MM. Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2017; 49:1602522.

[6] Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017; 49:1601792.

[7] Meng Y, Haichu W, Yuan W, Jie D. Precision monitoring of antithrombotic therapy in cardiovascular disease. Cardiovasc Innov Appl. 2024; 9.

[8] Deng L, Quan R, Yang Y, et al. Characteristics and long-term survival of patients with chronic thromboembolic pulmonary hypertension in China. Respirology. 2021; 26: 196-203.

[9] Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021; 57:2002828.

[10] Alba GA, Atri D, Darbha S, et al. Chronic thromboembolic pulmonary hypertension: the bench. Curr Cardiol Rep. 2021; 23:141.

[11] Liu J, Yang P, Tian H, et al. Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. J Transl Int Med. 2022; 10: 125-133.

[12] Jurida L, Werner S, Knapp F, et al. A common gene signature of the right ventricle in failing rat and human hearts. Nat Cardiovasc Res. 2024; 3: 819-840.

[13] Neto-Neves EM, Brown MB, Zaretskaia MV, et al. Chronic embolic pulmonary hypertension caused by pulmonary embolism and vascular endothelial growth factor inhibition. Am J Pathol. 2017; 187: 700-712.

[14] Arias-Loza PA, Jung P, Abeßer M, et al. Development and characterization of an inducible rat model of chronic thromboembolic pulmonary hypertension. Hypertension. 2016; 67: 1000-1005.

[15] Gonzalez-Hermosillo LM, Cueto-Robledo G, Navarro-Vergara DI, et al. Molecular pathophysiology of chronic thromboembolic pulmonary hypertension: a clinical update from a basic research perspective. Adv Respir Med. 2024; 92: 485-503.

[16] Guignabert C, Aman J, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. Eur Respir J. 2024; 64:2401095.

[17] Brandt M, Giokoglu E, Garlapati V, et al. Pulmonary arterial hypertension and endothelial dysfunction is linked to NADPH oxidase-derived superoxide formation in venous thrombosis and pulmonary embolism in mice. Oxidative Med Cell Longev. 2018; 2018:1860513.

[18] Sharma S, Hofbauer TM, Ondracek AS, et al. Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis. Blood. 2021; 137: 1104-1116.

[19] Li CY, Deng W, Liao XQ, Deng J, Zhang YK, Wang DX. The effects and mechanism of ginsenoside Rg1 on myocardial remodeling in an animal model of chronic thromboembolic pulmonary hypertension. Eur J Med Res. 2013; 18:16.

[20] Chen M, Wu Q, Shao N, et al. The significance of CD16+ monocytes in the occurrence and development of chronic thromboembolic pulmonary hypertension: insights from single-cell RNA sequencing. Front Immunol. 2024; 15:1446710.

[21] Zagorski J, Neto-Neves E, Alves NJ, Fisher AJ, Kline JA. Modulation of soluble guanylate cyclase ameliorates pulmonary hypertension in a rat model of chronic thromboembolic pulmonary hypertension by stimulating angiogenesis. Physiol Rep. 2022; 10:e15156.

[22] Karpov AA, Anikin NA, Mihailova AM, et al. Model of chronic thromboembolic pulmonary hypertension in rats caused by repeated intravenous administration of partially biodegradable sodium alginate microspheres. Int J Mol Sci. 2021; 22:1149.

[23] Karpov AA, Mihailova AM, Shilenko LA, et al. Inhibition of JAK1,2 prevents fibrotic remodeling of pulmonary vascular bed and improves outcomes in the rat model of chronic thromboembolic pulmonary hypertension. Int J Mol Sci. 2022; 23:15646.

[24] Karpov AA, Vachrushev NS, Shilenko LA, et al. Sympathetic denervation and pharmacological stimulation of parasympathetic nervous system prevent pulmonary vascular bed remodeling in rat model of chronic thromboembolic pulmonary hypertension. J Cardiovasc Dev Dis. 2023; 10:40.

[25] Karpov AA, Mihailova AM, Cherepanov DE, et al. The use of microencapsulated autologous thrombi for modelling chronic thromboembolic pulmonary hypertension in rats. Bull Exp Biol Med. 2023; 175: 616-619.

[26] Karpov AA, Krylov AA, Shilenko LA, et al. Suppression of aseptic inflammation reduces the severity of pulmonary artery remodeling and improves the clinical course of experimental chronic thromboembolic pulmonary hypertension. J Evol Biochem Physiol. 2024; 60: 1248-1259.

[27] Zhang H, Lu X, Guo Z, et al. Development of a clinically relevant rat model of chronic thromboembolic pulmonary hypertension by combining splenectomy with pulmonary thromboembolism. Thromb Res. 2025; 249:109310.

[28] Quarck R, Wagenaar A, Tielemans B, et al. Abstract 12259: chronic thromboembolic pulmonary hypertension caused by combination of repeated clot embolization with inhibition of angiogenesis in rabbits. Circulation. 2019; 140(Suppl_1):A12259.

[29] Quarck R, Willems L, Tielemans B, et al. Impairment of angiogenesis-driven clot resolution is a key event in the progression to chronic thromboembolic pulmonary hypertension: validation in a novel rabbit model. Arterioscler Thromb Vasc Biol. 2023; 43: 1308-1321.

[30] Wakefield TW, Strieter RM, Downing LJ, et al. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J Surg Res. 1996; 64: 26-31.

[31] Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol. 1995; 15: 258-268.

[32] Millet J, Vaillot M, Theveniaux J, Brown NL. Experimental venous thrombosis induced by homologous serum in the rat. Thromb Res. 1996; 81: 497-502.

[33] Mercier O, Fadel E. Chronic thromboembolic pulmonary hypertension: animal models. Eur Respir J. 2013; 41: 1200-1206.

[34] Bonderman D, Jakowitsch J, Redwan B, et al. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2008; 28: 678-684.

[35] Chen HM, Duan YY, Li J, et al. A rabbit model with acute thrombo-embolic pulmonary hypertension created with echocardiography guidance. Ultrasound Med Biol. 2008; 34: 221-227.

[36] Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017; 26:160112.

[37] Stam K, van Duin RW, Uitterdijk A, et al. Pulmonary microvascular remodeling in chronic thrombo-embolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2018; 315: L951-L964.

[38] Zabini D, Heinemann A, Foris V, et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2014; 44: 951-962.

[39] Shelub I, van Grondelle A, McCullough R, Hofmeister S, Reeves JT. A model of embolic chronic pulmonary hypertension in the dog. J Appl Physiol Respir Environ Exerc Physiol. 1984; 56: 810-815.

[40] Moser KM, Cantor JP, Olman M, et al. Chronic pulmonary thromboembolism in dogs treated with tranexamic acid. Circulation. 1991; 83: 1371-1379.

[41] Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J. 2000; 15(4): 640-648.

[42] Mulchrone A, Kellihan HB, Forouzan O, et al. A large animal model of right ventricular failure due to chronic thromboembolic pulmonary hypertension: a focus on function. Front Cardiovasc Med. 2018; 5:189.

[43] Weimann J, Zink W, Schnabel PA, et al. Selective vasodilation by nitric oxide inhalation during sustained pulmonary hypertension following recurrent microembolism in pigs. J Crit Care. 1999; 14(3): 133-140.

[44] Sage E, Mercier O, Herve P, et al. Right lung ischemia induces contralateral pulmonary vasculopathy in an animal model. J Thorac Cardiovasc Surg. 2012; 143: 967-973.

[45] Guihaire J, Haddad F, Boulate D, et al. Non-invasive indices of right ventricular function are markers of ventricular-arterial coupling rather than ventricular contractility: insights from a porcine model of chronic pressure overload. Eur Heart J Cardiovasc Imaging. 2013; 14: 1140-1149.

[46] García-Álvarez A, Fernández-Friera L, García-Ruiz JM, et al. Noninvasive monitoring of serial changes in pulmonary vascular resistance and acute vasodilator testing using cardiac magnetic resonance. J Am Coll Cardiol. 2013; 62: 1621-1631.

[47] Mercier O, Tivane A, Dorfmüller P, et al. Piglet model of chronic pulmonary hypertension. Pulm Circ. 2013; 3: 908-915.

[48] Noly PE, Haddad F, Arthur-Ataam J, et al. The importance of capillary density-stroke work mismatch for right ventricular adaptation to chronic pressure overload. J Thorac Cardiovasc Surg. 2017; 154: 2070-2079.

[49] Stam K, Cai Z, van der Velde N, et al. Cardiac remodelling in a swine model of chronic thromboembolic pulmonary hypertension: comparison of right vs. left ventricle. J Physiol. 2019; 597: 4465-4480.

[50] Stam K, van Duin RWB, Uitterdijk A, Cai Z, Duncker DJ, Merkus D. Exercise facilitates early recognition of cardiac and vascular remodeling in chronic thromboembolic pulmonary hypertension in swine. Am J Physiol Heart Circ Physiol. 2018; 314: H627-h642.

[51] Boulate D, Amsallem M, Menager JB, et al. Induction and phenotyping of acute right heart failure in a large animal model of chronic thromboembolic pulmonary hypertension. J Vis Exp. 2022; 181.

[52] Mendoza-Zambrano E, Sánchez-López V, Gómez-Rodríguez B, et al. Role of extracellular vesicles in chronic post-embolic pulmonary hypertension: data from an experimental animal model and patients. Biomedicine. 2025; 13:1499.

[53] Pohlmann JR, Akay B, Camboni D, Koch KL, Mervak BM, Cook KE. A low mortality model of chronic pulmonary hypertension in sheep. J Surg Res. 2012; 175: 44-48.

[54] Ukita R, Tipograf Y, Tumen A, et al. Left pulmonary artery ligation and chronic pulmonary artery banding model for inducing right ventricular-pulmonary hypertension in sheep. ASAIO J. 2021; 67: e44-e48.

[55] Johnson CA Jr, Cortelli M Jr, Glomp G, et al. A dynamic sheep model to induce pulmonary hypertension and right ventricular failure. Methods Mol Biol. 2024; 2803: 239-258.

[56] Stam K, Clauss S, Taverne Y, Merkus D. Chronic thromboembolic pulmonary hypertension—what have we learned from large animal models. Front Cardiovasc Med. 2021; 8:574360.

[57] Yun T, Xuan M, Zhixiang D, et al. Cardiac magnetic resonance visualization of the myocardial microstructure in non-ischemic cardiomyopathies. Cardiovasc Innov Appl. 2024; 9.

[58] Boulate D, Perros F, Dorfmuller P, et al. Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2015; 34: 457-467.

[59] Aguero J, Ishikawa K, Fish KM, et al. Combination proximal pulmonary artery coiling and distal embolization induces chronic elevations in pulmonary artery pressure in swine. PLoS One. 2015; 10:e0124526.

[60] Rothman A, Wiencek RG, Davidson S, et al. Challenges in the development of chronic pulmonary hypertension models in large animals. Pulm Circ. 2017; 7: 156-166.

[61] Noly PE, Piquereau J, Coblence M, et al. Right ventricular mitochondrial respiratory function in a piglet model of chronic pulmonary hypertension. J Thorac Cardiovasc Surg. 2020; 159: 129-140.

[62] Perkett EA, Brigham KL, Meyrick B. Continuous air embolization into sheep causes sustained pulmonary hypertension and increased pulmonary vasoreactivity. Am J Pathol. 1988; 132(3): 444-454.

[63] Zhou X, Wang D, Castro CY, et al. A pulmonary hypertension model induced by continuous pulmonary air embolization. J Surg Res. 2011; 170:e11-e16.

[64] Mertz M, Hetzel T, Alex K, et al. Interdisciplinary animal research ethics-challenges, opportunities, and perspectives. Animals (Basel). 2024; 14:2896.

[65] Bertout JA, Baneux PJR, Robertson-Plouch CK. Recommendations for ethical review of veterinary clinical trials. Front Vet Sci. 2021; 8:715926.

[66] Jiawei Z, Dongfang Y, Jianling B, et al. Machine learning methods in real-world studies of cardiovascular disease. Cardiovasc Innov Appl. 2023; 7.

[67] Kachabi A, Colebank MJ, Chesler NC. Subject-specific one-dimensional fluid dynamics model of chronic thromboembolic pulmonary hypertension. Biomech Model Mechanobiol. 2024; 23: 469-483.

[68] Cárdenes N, Sembrat J, Noda K, et al. Human ex vivo lung perfusion: a novel model to study human lung diseases. Sci Rep. 2021; 11:490.

[69] Li N, Gou S, Wang J, et al. CRISPR/Cas9-mediated gene correction in newborn rabbits with hereditary tyrosinemia type I. Mol Ther. 2021; 29: 1001-1015.

[70] Cao J, Guo Z, Xu X, et al. Advances in CRISPR-Cas9 in lineage tracing of model animals. Animal Model Exp Med. 2025; 8(6): 1004-1022.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.